Fosun Pharma (600196) Announces Acceptance of Subsidiary’s Cisplatin Injection Registration Application

Bulletin Express

Feb 13

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical Products Administration for its Cisplatin Injection registration application. This chemical drug is indicated for metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.

As of January 2026, Fosun Pharma’s total research and development investment in Cisplatin Injection amounted to 4.69 million renminbi. According to IQVIA CHPA data, sales of Cisplatin Injection in China for 2024 reached approximately 165.00 million renminbi. The acceptance of this application does not guarantee commercial approval, and subsequent market performance will depend on various factors including market demand and competition.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1116626955"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116626955\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116626955?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 18:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116626955","market":"us","top_or_hot":-1,"title":"Fosun Pharma (600196) Announces Acceptance of Subsidiary’s Cisplatin Injection Registration Application","media":"Bulletin Express","content":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical Products Administration for its Cisplatin Injection registration application. This chemical drug is indicated for metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.</p>\n<p>As of January 2026, Fosun Pharma’s total research and development investment in Cisplatin Injection amounted to 4.69 million renminbi. According to IQVIA CHPA data, sales of Cisplatin Injection in China for 2024 reached approximately 165.00 million renminbi. The acceptance of this application does not guarantee commercial approval, and subsequent market performance will depend on various factors including market demand and competition.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (600196) Announces Acceptance of Subsidiary’s Cisplatin Injection Registration Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (600196) Announces Acceptance of Subsidiary’s Cisplatin Injection Registration Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-13 18:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical Products Administration for its Cisplatin Injection registration application. This chemical drug is indicated for metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.</p>\n<p>As of January 2026, Fosun Pharma’s total research and development investment in Cisplatin Injection amounted to 4.69 million renminbi. According to IQVIA CHPA data, sales of Cisplatin Injection in China for 2024 reached approximately 165.00 million renminbi. The acceptance of this application does not guarantee commercial approval, and subsequent market performance will depend on various factors including market demand and competition.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1116626955","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116626955","pubTimestamp":1770976897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(600196)公告子公司顺铂注射液注册申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, 600196) reported that Jisimei (Wuhan) Pharmaceutical Co., Ltd., a subsidiary, recently received acceptance from the National Medical Products Administration for its Cisplatin Injection registration application. This chemical drug is indicated for metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.\nAs of January 2026, Fosun Pharma’s total research and development investment in Cisplatin Injection amounted to 4.69 million renminbi. According to IQVIA CHPA data, sales of Cisplatin Injection in China for 2024 reached approximately 165.00 million renminbi. The acceptance of this application does not guarantee commercial approval, and subsequent market performance will depend on various factors including market demand and competition.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}